🔗 Share this article

While the US undertakes sweeping changes to its vaccine guidelines, one figure has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus shots in the global health crisis and has focused upon possible fatalities after COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Program

Agency leaders had intended to unveil major revisions to the pediatric vaccination calendar recently, aligning the US with Denmark’s immunization schedule, according to reports – a major change that would place the US out of alignment with a large portion of the global community with no evidence for improved outcomes. The announcement has been postponed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to lead the division this year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting certain pediatric immunization guidelines in the US to become more similar to the Danish model, a country with nationalized medicine and a population roughly the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Background

The appointee has little discernible track record in drug development, approval processes or leadership, which has been typical for previous heads of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who ran the center have had.”

CDER has an immense portfolio at the FDA, she emphasized.

“Many people just pays attention on the new drug program, but the generic program authorizes numerous generic medications. There’s a biologic copycat branch, over-the-counter program and more, and every single one must be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Additionally, a major administrative element to the role, which supervises more than 5,000 staff members. “It’s a huge management job, if you perform it correctly,” she added.

Response and Controversial Initiatives

Regarding questions about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on incorrect presumptions”.

“Her experience aligns with the duties of her role,” the official explained, noting the period Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that apparently concerned her former heads. “By what process are these medications being chosen for this expedited pathway? Who takes the decisions?” Howard said. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed regulations of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a clearer, if problematic, past, some experts have noted. She released a study using unverified crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccinations are riskier than they are.

Included in her “wish list” for the new government included altering rules for new vaccines and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the FDA, Høeg has reportedly proposed barring teenage boys from getting COVID-19 vaccinations.

“She is an complete true believer who starts off with her preconceived notions and tailors the evidence to retrofit the data in a extremely deceptive, untruthful fashion,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|